UI 018
Alternative Names: UI-018Latest Information Update: 28 Oct 2024
At a glance
- Originator Korea United Pharm Inc
- Class Antihyperlipidaemics; Vascular disorder therapies
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Vascular disorders
- No development reported Hyperlipidaemia
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for phase-I development in Hyperlipidaemia(In volunteers) in South Korea
- 06 Sep 2021 Phase-I clinical trials in Hyperlipidaemia (In volunteers) in South Korea (unspecified route) (NCT05085184)
- 30 Apr 2020 UI 018 is available for licensing as of 30 Apr 2020. https://www.kup.co.kr/research/innovation_main.htm